Xenon Seven

Director, Corporate Communications

Boston · Director

Sponsorship not specifiedDetected 14 days ago

RESTCRMClinical TrialsResearchLeadershipCommunicationCollaborationProblem SolvingPublic SpeakingOrganizational Skills

About the role

Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.

Responsibilities

Build strategies around and execute programming for corporate stakeholders including investors, media, investigators, partners and policymakers/influencers.
Collaborate with the CFO, CEO, Corporate Affairs and Executive Leadership team to craft clear, consistent messaging around company strategy, pipeline, and milestones.
Lead development of briefing materials for management in preparation for investor meetings.
Lead the discussions and development of IR/Industry conference presentations, panels/Q&As, PRs, through collaboration with subject matter experts and leaders across the organization, as well as materials reviews.
Drive and support preparation of earnings calls, press releases, and SEC filings (10-K, 10-Q, 8-K) in coordination with Finance and Legal.
Maintain Xenon's Investor Relations website, including ongoing maintenance and content updates as needed in collaboration with the website vendor.
Increase executive visibility and thought leadership via conference participation, thought leadership, panels and industry awards for the Executive Leadership Team and develop supporting external executive communications strategies and materials.
Work closely with the discovery and clinical teams on the emerging R&D portfolio and work, including developing external communications strategies and plans related to key milestones, how we will communicate to investors and other external stakeholders.
Support internal and external investigator communications by working closely with the R&D teams.
Partner with Corporate Affairs and Legal teams to ensure all external communications are accurate and consistent with corporate messaging including presentation decks, news releases, and all other content.

Requirements

Biotech or pharma industry experience is required
Issues management experience with a track record of successfully planning for and publicly addressing high profile business topics with key external stakeholders.
Highly organized, with attention to detail, adherence to deadlines, and ability to work under pressure with multiple, shifting priorities.
Travel will be required up to 15% both domestically and internationally.
Other duties as required.
10+ years of investor relations experience, ideally in the healthcare sector.
Strong communications expertise, including written, verbal, presentation, interpersonal skills, with the ability to translate and simplify complex scientific information and clinical data for research analysts and investors.
Proven track record of developing corporate and investor communication messaging and materials.
Experience developing executive level communications and engaging directly with senior management.
Superior interpersonal and external and internal customer relationship management skills.
Comprehensive understanding of the biotech industry, drug development and commercialization.
Comfortable operating in an agile environment but also possess solid experience successfully navigating the complexities of a growing organization.
Ability to build and retain in-depth knowledge of a company, business strategies & objectives to be able to develop innovative concepts that will work in the organization, and then effectively communicate and promote new ideas to ensure organizational buy-in.
Can consistently work with abstract ideas or situations across functional areas of the business, then through assessment of variables and assumptions, can identify strategies and solutions.

Nice to have

Bachelor's degree or equivalent, ideally with a specialization in Finance, Business, Life Sciences, or Communications
master's or advanced degree preferred.

Compensation

Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Company info

Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
What We Do:
We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
We are seeking a Director, Corporate Communications to join our team. The Director will be responsible for developing and executing communications strategies to promote and protect the Company's reputation, with a specific focus on Corporate, Investor, Executive and R&D communications. This leader will provide strategic execution of tactical implementation associated with corporate newsflow, including business updates, clinical trial milestones, data readouts and future product launches. This role will coordinate across internal stakeholders to deliver corporate messaging and programming to build the Xenon brand and reputation. The Director will also work to ensure external and internal communications are closely aligned to ensure teams are upholding our culture and shared values: Xenon CARES about patients, employees and those who put their trust in us.
Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
We are seeking a Director, Corporate Communications to join our team.
The Director will be responsible for developing and executing communications strategies to promote and protect the Company's reputation, with a specific focus on Corporate, Investor, Executive and R&D communications.
This leader will provide strategic execution of tactical implementation associated with corporate newsflow, including business updates, clinical trial milestones, data readouts and future product launches.
This role will coordinate across internal stakeholders to deliver corporate messaging and programming to build the Xenon brand and reputation.
The Director will also work to ensure external and internal communications are closely aligned to ensure teams are upholding our culture and shared values: Xenon CARES about patients, employees and those who put their trust in us.
Under the leadership of the Senior Vice President of Corporate Affairs, this role will also work with the CEO, CFO, CMO, CCO and other senior leaders to execute the Corporate and Investor Relations strategy, and effectively develop messaging and communications for our scientific, clinical, and financial progress to various stakeholder groups including investors, media and investigators.
This role will work closely with the Corporate Affairs team, Executive Leadership Team, as well as the discovery, clinical development, finance, legal and commercial departments to maintain an in-depth understanding of the company's operations, financial performance, and strategies.
This is a high-impact role ideal for a communications professional with corporate and investor communications experience who thrives in a dynamic, fast-paced biotech environment and can bridge science, strategy, and finance.
The ideal candidate has significant depth of expertise in understanding of business strategies and executive priorities and is a critical thinker with strong problem-solving skills.
The ideal candidate is also a strong communicator who collaborates effectively with key functions to communicate the corporate story.
Reporting to the Executive Director of Corporate Communications, this position will be part of the Corporate Affairs team and located in our Boston location, in Needham, MA, USA.

Apply directly at Xenon Seven →Create a free account for alerts like this View Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.